Published in Cancer Weekly, April 26th, 2005
Study 1: An investigator reviews immunobiologic therapies for myelodysplastic syndrome in a recent issue of Best Practice and Research Clinical Haematology.
"Recent progress in understanding the pathobiology of the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have led to the development of various immunologically oriented therapies for these diseases. The existence of elevated levels of tumor necrosis factor-alpha (TNF-alpha) in bone marrow during early stages of MIDS, and the possibility that TNF-alpha suppresses normal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.